Biopharma contributes to key global health discussions at WHA69
Find out here our take on the 69th World Health Assembly (WHA69) with some key relevant links included!
Read More
Pharmacovigilance of biotherapeutic medicines
A new study released in June 2016 identifying global case studies illustrating successes and challenges. A must read!
Read More
Our response to Zika virus
Check here about the R&D blueprint against Zika
Read More
Women’s Cancer Initiative in the Americas
Partnership to improve prevention of women’s cancers and quality of cancer registries in LAC reaches 1 year milestone
Read More
Latest News
2017-05-31 18:18:44
IFPMA contribution to key global health discussions @WHA70 (22-31 May 2017)
Geneva, 31 May 2017 – Starting with the election of Dr Tedros Adhanom Ghebreyesus as Director-General of the World Health ...
Read More2017-05-18 13:30:05
New Alliance to Drive and Measure Industry Progress to Curb Antimicrobial Resistance
New Industry Alliance brings together research-based pharmaceutical companies, generics, biotech and diagnostic companies, to drive ...
Read More2017-05-02 07:50:20
Fumie Griego joins International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) as new Assistant Director General
IFPMA Director-General Thomas Cueni announced today that former PhRMA and Merck KGaA executive, Dr Fumie ...
Read More2017-04-17 18:00:39
Progress report on biopharmaceutical industry contributions to the global fight against Neglected Tropical Diseases (NTDs)
109 active R&D projects for NTDs, of which over 90% are collaborative involving over 50 ...
Read More2017-03-09 16:32:44
EBE, EFPIA and IFPMA have today launched a position paper entitled “Considerations for physicians on switching decisions regarding biosimilars”.
Switching describes a physician’s decision to exchange one product that a patient receives for another. ...
Read More2017-02-28 07:57:57
IFPMA launches new policy principles and report on Rare Disease Day 2017 to benefit patients, healthcare and society
New set of policy principles outlines critical elements for a global framework on rare disease ...
Read More2017-02-10 09:30:19
IFPMA launches its 2017 facts & figures report
Geneva, 10 February 2017 – IFPMA has just published its 2017 facts & figures report ...
Read More
Latest Statement
2017-08-30 16:15:35
IFPMA Statement on UHC at 67th Session of the WHO Regional Committee for Africa
Delivered by Cyntia Genolet, Manager, Regulatory and Health Policy 30th August, Victoria Falls, Republic of Zimbabwe – Thank you for ...
Read More2017-08-30 14:33:29
IFPMA Statement on Yellow Fever at 67th Session of the WHO Regional Committee for Africa
Geneva, 10 February 2017 – IFPMA has just published its ...
Read More2017-06-06 21:37:25
IFPMA Statement to New Essential Medicines List
Geneva, 10 February 2017 – IFPMA has just published its ...
Read More2017-05-30 15:33:37
WHO WHA 70 agenda item 15.6 Cancer prevention and control in the context of an integrated approach
Geneva, 10 February 2017 – IFPMA has just published its ...
Read More2017-05-29 13:47:29
WHO WHA 70 agenda item 15.2 Draft global action plan on the public health response to dementia
Geneva, 10 February 2017 – IFPMA has just published its ...
Read More2017-05-29 09:01:04
WHO WHA 70 item 13.6 Member State mechanism on SSFFC
Geneva, 10 February 2017 – IFPMA has just published its ...
Read More2017-05-27 10:35:37
WHO WHA 70 agenda item 13.3 Addressing the global shortage of, and access to, medicines and vaccines
Geneva, 10 February 2017 – IFPMA has just published its ...
Read More
mailto:s.kaenzig@ifpma.org +41 22 338 32 49
direct line
Twitter skaenzig
Sadia Kaenzig - Communications Manager
Sadia manages communications on issues including regulatory, intellectual property protection, trade and the economic footprint of the research-based pharmaceutical industry, research and development ecosystem and innovation, vaccines including influenza vaccines, and biotherapeutics.
mailto:m.depol@ifpma.org +41 22 338 32 20
direct line
Twitter @MorganePol
Morgane De Pol - Communications and Public Affairs
Morgane manages communications on issues including the research-based pharmaceutical industry’s commitment to achieving sustainable and inclusive development, advancing Universal Health Coverage, designing transformational partnerships to build healthier societies, boosting innovation for neglected tropical diseases, expanding access to high quality treatments for infectious and chronic diseases, fighting counterfeit medicines, and promoting resilient and efficient health systems.
Our Brouchure
2015 Edition
A shared commitment to global health
At IFPMA we advocate policies and practices that encourage the discovery of and access to life-saving and life-enhancing medicines and vaccines, for people everywhere.
Our Logo
Full colour EPS format
Our Logo
Full colour PNG format
FULL Name LOGO
Full colour EPS format
FULL Name LOGO
Full colour PNG format
Hot Topic
Pharmacovigilance: Do your bit, play your part!
Pharmacovigilance is one of the key steps to ensuring the safety of all our medicines, including biotherapeutics and vaccines. It encourages an ongoing cycle of communication between patients, health professionals, regulatory authorities, and our biopharma industry which is
Read MoreInterview
IFPMA 2015 interview series 'Biodiversity, human health, and pharma'
A must-watch: Dr Manisha A. Desai, assistant general patent counsel at Eli Lilly and Company, gives her take on the importance of the Convention of Biodiversity and the Nagoya Protocol for the pharma industry. What's key is to
Read MoreOur Blog
What you need to know about dementia so that you don’t forget
September is World Alzheimer’s Month, an international campaign to challenge the stigma that surrounds dementia, a disease that affects almost 150,000 people in Switzerland. It is the third most frequent cause of death in the country, costing over CHF 7 billion a year – and as many as 400,000 predominantly elderly Swiss people may live with it by 2040. More than 27,000 Swiss are newly...
Read More
The trade routes of counterfeits
I have not forgotten the Chinese taxi driver who wanted to sell me a Rolex for $100 in Singapore a while back. Nor have I forgotten his absolute fury when I laughed and told him that if I wanted to buy a fake Rolex, I could have done it in Bangkok for $5. Since then, little has changed in the sad business of counterfeiting. Singapore,...
Read More
Beware of doomsday scenarios for health care spending
Fair pricing activists applauded the news earlier this month that the FDA approved another drug to cure hepatitis C. That this new medicine is cheaper and treats people quicker than the existing hepatitis C drugs goes to show how fast healthy competition can change the outlook on health spending. Not long ago, health economists were promoting a doomsday scenario that the new crop of hepatitis C drugs...
Read MoreLatest Tweets
@IFPMA @IFPMA @IFPMA @IFPMA @IFPMA 